Solid Biosciences (SLDB) EPS (Weighted Average and Diluted) (2020 - 2026)
Solid Biosciences' (SLDB) quarterly EPS (Weighted Average and Diluted) came in at -$0.52 in Q1 2026, up 11.86% year-on-year from -$0.46 in Q1 2025, and up 1.89% quarter-over-quarter from -$0.53 in Q4 2025.
Solid Biosciences (SLDB) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Solid Biosciences has disclosed EPS (Weighted Average and Diluted) across 7 years of filings, most recently posting -$0.52 for Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.52, up 11.86% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.95 (up 35.22% YoY), and the FY2025 annual result was -$1.99, up 34.97% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.52 for Q1 2026 at Solid Biosciences, up from -$0.53 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.42 in Q2 2025 to a low of -$3.37 in Q1 2022.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.79 (2024), against an average of -$1.21.
- Peak annual rise in EPS (Weighted Average and Diluted) reached 72.36% in 2022, while the deepest fall reached 1858.82% in 2022.
- Solid Biosciences' EPS (Weighted Average and Diluted) stood at -$0.68 in 2022, then plunged by 47.06% to -$1.0 in 2023, then dropped by 2.0% to -$1.02 in 2024, then surged by 48.04% to -$0.53 in 2025, then increased by 1.89% to -$0.52 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.52 (Q1 2026), -$0.53 (Q4 2025), and -$0.48 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 0.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -0.61 |
| 10 | Solid Biosciences | 789.54 Mn | 408.86 Mn | - | -0.52 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.52 |
| Dec 31, 2025 | -0.53 |
| Sep 30, 2025 | -0.48 |
| Jun 30, 2025 | -0.42 |
| Mar 31, 2025 | -0.59 |
| Dec 31, 2024 | -1.02 |
| Sep 30, 2024 | -0.79 |
| Jun 30, 2024 | -0.61 |
| Mar 31, 2024 | -0.64 |
| Dec 31, 2023 | -1.00 |
| Sep 30, 2023 | -1.05 |
| Jun 30, 2023 | -1.25 |
| Mar 31, 2023 | -1.54 |
| Dec 31, 2022 | -0.68 |
| Sep 30, 2022 | -2.71 |
| Jun 30, 2022 | -3.33 |
| Mar 31, 2022 | -3.37 |
| Dec 31, 2021 | -2.46 |
| Sep 30, 2021 | -2.40 |
| Jun 30, 2021 | -0.17 |